Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Opinion

Cannabis for chronic pain: Not a simple solution

Xavier F. Jimenez, MD
Cleveland Clinic Journal of Medicine December 2018, 85 (12) 950-952; DOI: https://doi.org/10.3949/ccjm.85a.18089
Xavier F. Jimenez
Medical Director, Chronic Pain Rehabilitation Program, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jimenex2@ccf.org
  • Article
  • Info & Metrics
  • PDF
Loading

The narrative review by Modesto-Lowe et al1 in this issue on the potential therapeutic use of cannabis for peripheral neuropathy is only the latest in a vogue string of examinations on how medical marijuana may be used to manage complex conditions. While the authors should be lauded for acknowledging that the role of cannabis in treating peripheral neuropathy is far from settled (“the unknown” in their title), the high stakes involved warrant even more stringent scrutiny than they suggest.

See related article, page 943

We are in the midst of an epidemic of chronic opioid use with massive repercussions, and it did not start overnight. Mounting calls for liberalizing narcotic use across a broad range of pain conditions accumulated gradually during the patient-advocacy era of the 1990s, with supporting “evidence” coming mostly from small uncontrolled studies, anecdotal reports, and industry pressure.2 Although cannabis and opioids are not interchangeable, we should be cautious about concluding that cannabis is effective and that it should be used to treat chronic pain.

CHRONIC PAIN IS COMPLICATED

Peripheral neuropathy, by definition, is a chronic pain condition. Unlike acute pain, chronic pain is characterized by biologic, psychologic, and social complexities that require nuance to manage and study.

Such nuance is lacking in most recent reviews of the medical use of cannabis. The conditions in question are often studied as if they were transient and acute, eg, employing shortterm studies and rudimentary measures such as numeric pain-rating scales or other snapshots of pain intensity. Results of these shortsighted assessments are impossible to extrapolate to long-term outcomes.

Whether cannabis therapy for chronic pain conditions is sustainable remains to be seen. Outcomes in chronic pain should not be defined simply by pain reduction, but by other dimensions such as changes in pain-related disability and quality of life, development of pharmacologic tolerance or dependence, adverse effects, and other “collateral damage.” We are far from understanding these issues, which require highly controlled and regulated longitudinal studies.

A recent Cochrane review3 of the efficacy of cannabis-based medicines for chronic neuropathic pain found that harms might outweigh the benefits. The quality of evidence was rated as very low to moderate; the reviewers cited small sample sizes and exclusion of important subgroups of patients (eg, those with substance abuse or other psychiatric comorbidities). Such exclusions are the crux of a major problem with cannabis research: studies are not naturalistic. The gritty reality of chronic pain management is paramount, and failing to consider the high-risk biopsychosocial factors typical of patients with chronic pain is naïve and, frankly, dangerous.

COGNITIVE AND MOTIVATIONAL PROBLEMS

The true danger of cannabis lies in what we already know with certainty. As the authors discuss, cannabis undisputedly results in dose-dependent cognitive and motivational problems. If we are preaching physical therapy and home exercise to counter deconditioning, socialization to reverse depression, cognitive-behavioral therapy to increase coping, returning to work to prevent prolonged disability, and other active measures to prevent pain from becoming chronic, then why would we suggest treatments known to blunt motivation, energy, concentration, and overall mood? As a general central nervous system suppressant,4 cannabis works broadly against our best efforts to rehabilitate patients and restore their overall function.

ALL CANNABIS IS NOT THE SAME

The authors use the general term cannabis in their title, yet rightly unpack the differences between medical marijuana, tetrahydrocannabinol (THC), and cannabidiol (CbD). However, in the minds of untrained and pain-stricken patients seeking rapid relief and practical solutions, such distinctions are likely irrelevant.

The danger in the barrage of publications examining cannabis vs medical marijuana vs THC vs CBD is that they all communicate an unintentional yet problematic message: that marijuana of some sort for pain is acceptable to try. And in the face of financial pressures, changing legal landscapes, insurance coverage volatility, and access issues, are patients really going to always secure prescriptions for wellregulated CBD (lacking psychoactive THC) from thoughtful and well-informed physicians, or will they turn to convenient street suppliers?

Simplified perceptions of safety and efficacy across all cannabis products do not help. More troublesome would be to extrapolate safety to other forms of marijuana known to be dangerous, such as synthetic cannabinoids, which in some instances have been associated with catastrophic outcomes.5 The slippery slope is real: if the message becomes that some (or most) marijuana is benign or even therapeutic, what is to curb a widespread and unregulated epidemic?

YOUTH AT RISK

Some groups are more vulnerable than others to the potential negative effects of cannabis. In a study at a medical cannabis dispensary in San Francisco,6 adolescents and young adults used more marijuana than older users did and had higher rates of “use when bored” and eventual pharmacologic dependence. Sustained use of marijuana by young people places them at risk of serious psychiatric disorders, with numerous studies demonstrating the unfolding of schizophrenia, depression, bipolar disorder, and more.7

As the authors point out, cannabis may be contraindicated in those already burdened with mental health problems. If we recall that comorbid psychiatric disorders are the norm rather than the exception in chronic pain conditions,8 can we recommend cannabis therapy for most patients with chronic pain with confidence that it will not cause unintended problems? Evidence already shows that even well-established medical marijuana services attract (and perhaps unintentionally debilitate) a certain high-risk demographic: young, socioeconomically disadvantaged men with other comorbid psychiatric and substance use disorders, who ultimately rank poorly in functional health measures compared with the general population.9

NOT REEFER MADNESS, BUT REEFER CAUTION

I am not advocating the fear-mongering misinformation campaigns of the past. We should not exaggerate and warn about “reefer madness” or equate marijuana with untruths about random violence or complete bedlam. Nonetheless, concerns for widespread amotivation, worsening psychiatric states, chronic disability, and chemical dependence are very real.

Needed are tightly regulated, well-controlled, and long-term prospective studies involving isolated CBD formulations lacking THC. Over time, perhaps only formulations approved by the US Food and Drug Administration will be embraced. In the meantime, more comprehensive approaches should be recommended, such as team-based interdisciplinary rehabilitation programs that have shown efficacy in handling chronic pain complexities.10,11

If such steps are unlikely, physicians should nonetheless stand united in sending a message of cautious optimism regarding medical marijuana, educating their patients not only about recently advertised potential yet inconclusive benefits, but also about the well-known and actual certitudes of its harms for use in chronic pain management. There is plenty of bad and worse information to share with patients, and there is a slippery slope of epidemic proportions to be wary about.

  • Copyright © 2018 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Modesto-Lowe V,
    2. Bojka R,
    3. Alvarado C
    . Cannabis for peripheral neuropathy: The good, the bad, and the unknown. Cleve Clin J Med 2018; 85(12):943–949. doi:10.3949/ccjm.85a.17115
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Wailoo K
    . Pain: A Political History. Baltimore, MD: Johns Hopkins University Press; 2014.
  3. ↵
    1. Mucke M,
    2. Phillips T,
    3. Radbruch L,
    4. Petzke F,
    5. Hauser W
    . Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2018; 3:CD012182. doi:10.1002/14651858.CD012182.pub2
    OpenUrlCrossRefPubMed
  4. ↵
    1. Lucas CJ,
    2. Galettis P,
    3. Schneider J
    . The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018. Epub ahead of print. doi:10.1111/bcp.13710
    OpenUrlCrossRef
  5. ↵
    1. Patel NA,
    2. Jerry JM,
    3. Jimenez XF,
    4. Hantus ST
    . New-onset refractory status epilepticus associated with the use of synthetic cannabinoids. Psychosomatics 2017; 58(2):180–186. doi:10.1016/j.psym.2016.10.006
    OpenUrlCrossRef
  6. ↵
    1. Haug NA,
    2. Padula CB,
    3. Sottile JE,
    4. Vandrey R,
    5. Heinz AJ,
    6. Bonn-Miller MO
    . Cannabis use patterns and motives: a comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addict Behav 2017; 72:14–20. doi:10.1016/j.addbeh.2017.03.006
    OpenUrlCrossRef
  7. ↵
    1. Mammen G,
    2. Rueda S,
    3. Roerecke M,
    4. Bonato S,
    5. Lev-Ran S,
    6. Rehm J
    . Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry 2018; 79(4) pii:17r11839. doi:10.4088/JCP.17r11839
    OpenUrlCrossRef
  8. ↵
    1. Velly AM,
    2. Mohit S
    . Epidemiology of pain and relation to psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2017; pii:S0278-5846(17)30194-X. doi:10.1016/j.pnpbp.2017.05.012
    OpenUrlCrossRef
  9. ↵
    1. Fischer B,
    2. Ialomiteanu AR,
    3. Aeby S,
    4. Rudzinski K,
    5. Kurdyak P,
    6. Rehm J
    . Substance use, health, and functioning characteristics of medical marijuana program participants compared to the general adult population in Ontario (Canada). J Psychoactive Drugs 2017; 49(1):31–38. doi:10.1080/02791072.2016.1264648
    OpenUrlCrossRef
  10. ↵
    1. Shah A,
    2. Craner J,
    3. Cunningham JL
    . Medical cannabis use among patients with chronic pain in an interdisciplinary pain rehabilitation program: characterization and treatment outcomes. J Subst Abuse Treat 2017; 77:95–100. doi:10.1016/j.jsat.2017.03.012
    OpenUrlCrossRef
  11. ↵
    1. Stanos S
    . Focused review of interdisciplinary pain rehabilitation programs for chronic pain management. Curr Pain Headache Rep 2012; 16(2):147–152. doi:10.1007/s11916-012-0252-4
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 85 (12)
Cleveland Clinic Journal of Medicine
Vol. 85, Issue 12
1 Dec 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cannabis for chronic pain: Not a simple solution
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cannabis for chronic pain: Not a simple solution
Xavier F. Jimenez
Cleveland Clinic Journal of Medicine Dec 2018, 85 (12) 950-952; DOI: 10.3949/ccjm.85a.18089

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cannabis for chronic pain: Not a simple solution
Xavier F. Jimenez
Cleveland Clinic Journal of Medicine Dec 2018, 85 (12) 950-952; DOI: 10.3949/ccjm.85a.18089
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • CHRONIC PAIN IS COMPLICATED
    • COGNITIVE AND MOTIVATIONAL PROBLEMS
    • ALL CANNABIS IS NOT THE SAME
    • YOUTH AT RISK
    • NOT REEFER MADNESS, BUT REEFER CAUTION
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Cannabis for peripheral neuropathy: The good, the bad, and the unknown
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Opinion

  • Telemedicine: Past, present, and future
Show more Opinion

Editorial

  • Vitamin D: A metabolic bone disease perspective
  • Making best use of bone turnover markers to monitor oral bisphosphonate therapy
  • Laboratory stewardship should be a priority in every hospital
Show more Editorial

Similar Articles

Subjects

  • Pain
  • Mental Health
  • Drug Therapy

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire